The FDA has cleared the interleukin (IL)-23 inhibitor tildrakizumab (Ilumya) for the treatment of active psoriatic arthritis (PsA) in adults. Sun Pharma announced the approval on October 30. “As an IL-23 inhibitor administered exclusively by a healthcare provider, Ilumya is now an option for adults with active psoriatic arthritis whoContinue Reading
🛡️ Just a quick check We’re checking your connection to prevent automated abuse Read MoreContinue Reading
🛡️ Just a quick check We’re checking your connection to prevent automated abuse Read MoreContinue Reading
🛡️ Just a quick check We’re checking your connection to prevent automated abuse Read MoreContinue Reading
🛡️ Just a quick check We’re checking your connection to prevent automated abuse Read MoreContinue Reading
🛡️ Just a quick check We’re checking your connection to prevent automated abuse Read MoreContinue Reading
🛡️ Just a quick check We’re checking your connection to prevent automated abuse Read MoreContinue Reading
🛡️ Just a quick check We’re checking your connection to prevent automated abuse Read MoreContinue Reading
🛡️ Just a quick check We’re checking your connection to prevent automated abuse Read MoreContinue Reading
🛡️ Just a quick check We’re checking your connection to prevent automated abuse Read MoreContinue Reading
Skip to content